PACO NET INCOME CLIMBS 20% IN THIRD QUARTER TO $1.2 MIL.; FIRM ENTERS MARKETING PACT WITH "MAJOR" DRUG FIRM FOR PROPRIETARY CONTACT LENS CARE SOLUTIONS
Executive Summary
Paco's net income jumped 20% in the third quarter ended May 9 to $1.2 mil. despite an 11% decline in volume, from $10.7 mil. in the comparable 1986 period to $9.5 mil. For the first nine months of fiscal 1987, the drug packager's sales were flat at approximately $30 mil. Profits for the nine months ended May 9 were up 11% to $3.1 mil. Paco announced the signing of a supply agreement with "a major pharmaceutical company" covering Paco's proprietary contact lens care solutions. "Test marketing will commence during 1987 and the results of the tests will determine the eventual magnitude of the agreement," the company said. Repligen attributed an $18.1 mil. fourth quarter loss to a nonrecurring charge for the acquisition of technologies, including technology related to a prototype AIDS vaccine, from Centocor. "The $17.3 mil. charge represents the market value of Repligen common stock transferred to Centocor, minus $2.9 mil. in cash paid by Centocor to Repligen," the biotech firm explained. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth